✕
Get authentic, real-time news that helps you fight COVID-19 better.
Install for doctors. It's free.
Install for doctors. It's free.
Bharat Biotech's homegrown Covid-19 vaccine has shown an interim vaccine efficacy of 81% in late-stage clinical trials, the Indian company said on March 3. The interim analysis was based on 43 recorded cases of Covid-19 in the trial of 25,800 participants, conducted in partnership with the Indian government's medical research body.
Thirty-six of the 43 cases were recorded in participants who received a placebo, compared with seven cases in people who were given the Bharat Biotech vaccine, pointing to an efficacy rate of 80.6%, the company said. India had approved the vaccine, branded COVAXIN, in January without late-stage efficacy data, raising questions about its effectiveness.
India's vaccination drive, currently underway, includes COVAXIN and a vaccine developed by Oxford University and AstraZeneca. Earlier this week, Indian Prime Minister Narendra Modi was inoculated with the first dose of COVAXIN.
Source:
https://health.economictimes.indiatimes.com/news/pharma/bharat-biotech-says-covid-19-vaccine-shows-81-interim-efficacy/81311876
Thirty-six of the 43 cases were recorded in participants who received a placebo, compared with seven cases in people who were given the Bharat Biotech vaccine, pointing to an efficacy rate of 80.6%, the company said. India had approved the vaccine, branded COVAXIN, in January without late-stage efficacy data, raising questions about its effectiveness.
India's vaccination drive, currently underway, includes COVAXIN and a vaccine developed by Oxford University and AstraZeneca. Earlier this week, Indian Prime Minister Narendra Modi was inoculated with the first dose of COVAXIN.
Source:
https://health.economictimes.indiatimes.com/news/pharma/bharat-biotech-says-covid-19-vaccine-shows-81-interim-efficacy/81311876
1 / 1
1 share
Like
Comment
Share
